Johnson & Johnson (JNJ)
New long-term data reinforces TREMFYA® (guselkumab) as the only IL-23 inhibitor proven to substantially inhibit structural joint damage in active psoriatic arthritis
New long-term data reinforces TREMFYA® (guselkumab) as the only IL-23 inhibitor proven to substantially inhibit structural joint damage in active psoriatic arthritis
📈 **POSITIVE** • High confidence analysis (91%) • Strong positive clinical catalyst • Significant growth potential **Sentiment:** Positive (95%) **Content type:** Clinical